Acute coronary syndrome as a possible immune-related adverse event in a lung cancer patient achieving a complete response to anti-PD-1 immune checkpoint antibody

Annals of Oncology

Volumn 28, Issue 11, 2017, Pages 2893-2895

  Tomita, Y ^a   Sueta, D ^a   Kakiuchi, Y ^a   Saeki, S ^a   Saruwatari, K ^a   Sakata, S ^a   Jodai, T ^a   Migiyama, Y ^a   Akaike, K ^a   Hirosako, S ^a   Fujisue, K ^a   Yamamura, S ^a   Miyazaki, S ^a   Takashio, S ^a   Izumiya, Y ^a   Nakamura, K ^a   Tsujita, K ^a   Ichiyasu, H ^a   Fujii, K ^a  

^a KUMAMOTO UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ATORVASTATIN; CISPLATIN; CORTICOSTEROID; NIVOLUMAB; ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY; PDCD1 PROTEIN, HUMAN; PROGRAMMED DEATH 1 RECEPTOR;

ACUTE CORONARY SYNDROME; ADULT; ATHEROMA; CANCER CHEMOTHERAPY; CASE REPORT; CLINICAL ARTICLE; CORONARY ANGIOGRAPHY; DYSLIPIDEMIA; ERYTHEMA MULTIFORME; FEVER; FIBROATHEROMA; HUMAN; HYPERTHYROIDISM; HYPOTHYROIDISM; INTERSTITIAL PNEUMONIA; LETTER; LUNG ADENOCARCINOMA; MALE; MIDDLE AGED; MULTIPLE CYCLE TREATMENT; OPTICAL COHERENCE TOMOGRAPHY; POSITRON EMISSION TOMOGRAPHY-COMPUTED TOMOGRAPHY; PRIORITY JOURNAL; SMOKING; THROMBUS; ADENOCARCINOMA; ANTAGONISTS AND INHIBITORS; CHEMICALLY INDUCED; DIAGNOSTIC IMAGING; IMMUNOLOGY; LUNG TUMOR;

ACUTE CORONARY SYNDROME; ADENOCARCINOMA; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CISPLATIN; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; PROGRAMMED CELL DEATH 1 RECEPTOR;

EID: 85034035820     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdx326     Document Type: Letter

References (7)

1. Foks AC, Kuiper J. Immune checkpoint proteins: exploring their therapeutic potential to regulate atherosclerosis. Br J Pharmacol 2017; doi: 10.1111/bph.13802. [Epub ahead of print]
2. Johnson DB, Balko JM, ComptonML et al. Fulminant myocarditis with combination immune checkpoint blockade. N Engl JMed 2016; 375: 1749-1755
3. Naidoo J, Wang X, Woo KM et al. Pneumonitis in patients treated with anti-programmed death-1/programmed death ligand 1 therapy. J Clin Oncol 2017; 35: 709-717
4. Naidoo J, Page DB, Li BT et al. Toxicities of the anti-PD-1 and anti-PDL1 immune checkpoint antibodies. Ann Oncol 2015; 26: 2375-2391
5. Freeman-Keller M, KimY, Cronin H et al. Nivolumab in resected and unresectable metastatic melanoma: characteristics of immune-related adverse events and association with outcomes. Clin Cancer Res 2016; 22: 886-894
6. Borghaei H, Paz-Ares L, Horn L et al. Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. N Engl J Med 2015; 373: 1627-1639
7. Brahmer J, Reckamp KL, Baas P et al. Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer. N Engl J Med 2015; 373: 123-135